Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) ROCE %: 27.94% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600211 Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
94 GF Score
Price ¥39.30
GF Value ¥40.53
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Tibet Rhodiola Pharmaceutical Holding Co ROCE %?

Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211 +1.39% 94 ROCE % is 27.94% as of Mar. 2026. GuruFocus rates SHSE:600211 with a GF Score™ of 94/100 and a GF Value™ of ¥40.53 (Fairly Valued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tibet Rhodiola Pharmaceutical Holding Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 27.94%.

Tibet Rhodiola Pharmaceutical Holding Co  (SHSE:600211) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tibet Rhodiola Pharmaceutical Holding Co ROCE % Related Terms

Tibet Rhodiola Pharmaceutical Holding Co ROCE % Historical Data

* Premium members only.

The historical data trend for Tibet Rhodiola Pharmaceutical Holding Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tibet Rhodiola Pharmaceutical Holding Co ROCE % Chart

Tibet Rhodiola Pharmaceutical Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.77 16.57 28.10 31.46 24.47

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.43 32.18 16.17 21.21 27.94
SHSE:600211
94GF Score
Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tibet Rhodiola Pharmaceutical Holding Co ROCE % Calculation

Tibet Rhodiola Pharmaceutical Holding Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=1053.187/( ( (4747.338 - 766.571) + (6267.387 - 1640.126) )/ 2 )
=1053.187/( (3980.767+4627.261)/ 2 )
=1053.187/4304.014
=24.47 %

Tibet Rhodiola Pharmaceutical Holding Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=1307.148/( ( (6267.387 - 1640.126) + (6391.813 - 1662.702) )/ 2 )
=1307.148/( ( 4627.261 + 4729.111 )/ 2 )
=1307.148/4678.186
=27.94 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 27.94% mean?
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a ROCE % of 27.94% as of Mar. 2026.
Is Tibet Rhodiola Pharmaceutical Holding Co's ROCE % too high?
Tibet Rhodiola Pharmaceutical Holding Co's current ROCE % is 27.94%. The Drug Manufacturers industry median ROCE % is 7.04. Tibet Rhodiola Pharmaceutical Holding Co's value of 27.94% is 296.9% above this industry median. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's ROCE % compare to ZTS and UTHR?
Tibet Rhodiola Pharmaceutical Holding Co's ROCE % of 27.94% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. Tibet Rhodiola Pharmaceutical Holding Co's value of 27.94% is 296.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tibet Rhodiola Pharmaceutical Holding Co's current ROCE % of 27.94% is 296.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tibet Rhodiola Pharmaceutical Holding Co's current ROCE % is 27.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.53, compared to a current price of ¥39.30 — trading 3% below its estimated fair value. The current ROCE % is 27.94% and 296.9% above the Drug Manufacturers industry median of 7.04. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current ROCE % is 27.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?

Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued. The current stock price of ¥39.30 is trading 3% below its estimated GF Value™ of ¥40.53. GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.

Key valuation signals for SHSE:600211:

  • ROCE %: 27.94%
  • GF Value™: ¥40.53 vs. price of ¥39.30 (3% below fair value)
  • GF Score™: 94/100 with 2 warning signs
  • Industry Position: 296.9% above the Drug Manufacturers median

No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tibet Rhodiola Pharmaceutical Holding Co Business Description

Address No. 3 Guangzhou Road, Area A, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score

Get the complete analysis for SHSE:600211

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥39.30
Price
¥40.53
GF Value